KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBT Margin: 2009-2025

Historic EBT Margin for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to -1,461.25%.

  • Arbutus Biopharma's EBT Margin rose 1164.00% to -1,461.25% in Q3 2025 from the same period last year, while for Sep 2025 it was -289.31%, marking a year-over-year increase of 84809.00%. This contributed to the annual value of -1,133.04% for FY2024, which is 73147.00% down from last year.
  • Latest data reveals that Arbutus Biopharma reported EBT Margin of -1,461.25% as of Q3 2025, which was down 6,371.92% from 23.30% recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's EBT Margin registered a high of 23.30% during Q2 2025, and its lowest value of -1,472.89% during Q3 2024.
  • For the 3-year period, Arbutus Biopharma's EBT Margin averaged around -850.16%, with its median value being -900.33% (2023).
  • Per our database at Business Quant, Arbutus Biopharma's EBT Margin slumped by 104,129bps in 2024 and then surged by 116,976bps in 2025.
  • Arbutus Biopharma's EBT Margin (Quarterly) stood at -665.03% in 2021, then spiked by 31,384bps to -351.19% in 2022, then slumped by 54,913bps to -900.33% in 2023, then soared by 10,623bps to -794.09% in 2024, then surged by 1,164bps to -1,461.25% in 2025.
  • Its last three reported values are -1,461.25% in Q3 2025, 23.30% for Q2 2025, and -1,390.59% during Q1 2025.